(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide hydrate
≥99.8%
- Product Code: 184681
CAS:
1042385-75-0
| Molecular Weight: | 487.95 g./mol | Molecular Formula: | C₂₄H₂₇ClFN₅O₃ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD19443734 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, dry, sealed |
Product Description:
Used in targeted cancer therapies, particularly in the treatment of non-small cell lung cancer (NSCLC). It functions as an irreversible inhibitor of the epidermal growth factor receptor (EGFR), including mutant forms such as T790M and exon 19 deletions, which are associated with tumor growth and resistance to earlier-generation drugs. By selectively blocking EGFR signaling pathways, it suppresses cancer cell proliferation and promotes apoptosis. Its irreversible binding enhances potency and duration of action, making it effective in patients who have developed resistance to other EGFR inhibitors. The compound is designed for oral administration and has shown clinical efficacy in reducing tumor size and improving progression-free survival in advanced stages of the disease.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 250mg | 10-20 days | ฿990.00 |
+
-
|
| 1g | 10-20 days | ฿5,000.00 |
+
-
|
| 5g | 10-20 days | ฿18,000.00 |
+
-
|
(E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)-4-(piperidin-1-yl)but-2-enamide hydrate
Used in targeted cancer therapies, particularly in the treatment of non-small cell lung cancer (NSCLC). It functions as an irreversible inhibitor of the epidermal growth factor receptor (EGFR), including mutant forms such as T790M and exon 19 deletions, which are associated with tumor growth and resistance to earlier-generation drugs. By selectively blocking EGFR signaling pathways, it suppresses cancer cell proliferation and promotes apoptosis. Its irreversible binding enhances potency and duration of action, making it effective in patients who have developed resistance to other EGFR inhibitors. The compound is designed for oral administration and has shown clinical efficacy in reducing tumor size and improving progression-free survival in advanced stages of the disease.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :